UK study to look at semaglutide for alcohol addiction and obesity The four-year trial will aim to help “guide future care” for alcohol-related liver disease and obesity in the UK.…
Trust commissions benzodiazepine review following patient death A patient died by suicide after being permanently prescribed diazepam without a required medical review while awaiting a re-titration of her clozapine prescription.…
MHRA approves orforglipron weight-loss pill The Medicines and Healthcare products Regulatory Agency said its approval of orforglipron makes the UK the first country in Europe to authorise the medication.…
UK patients being recruited for ribupatide trials Researchers will assess the efficacy of up to 10mg doses of weight-loss drug ribupatide in patients with or without diabetes over around an 18-month period.…
Incretin-based weight-loss drugs should not be deliberately continued in pregnancy, consensus guidelines state The guidelines have been drawn up by a multidisciplinary group of experts following a systematic scoping review.…
Best practice for prescribing drugs with dependence potential An overview of the considerations for prescribing medicines with the risk of dependency, including monitoring, discontinuation and the optimisation of therapeutic outcomes.…
Around one in five adults would share weight-loss jabs with friends, survey finds A Pharmacy2U-commissioned survey also found that more than one-quarter of UK adults said that they would share oral weight-loss medication with friends or family.…
Switching between weight-loss medications This article proposes practical approaches for safe, effective switching between tirzepatide and semaglutide.…
Health news round-up: coffee, ADHD prescribing, and GLP-1s and hair loss The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
Novo Nordisk sues Eli Lilly over ‘misleading’ GLP-1 advertising Novo Nordisk claims that Lilly’s advertising campaigns intentionally used outdated studies to offer “proof of broad, product-level superiority” of its Zepbound and Mounjaro products over Novo Nordisk’s Wegovy and Ozempic products.…
